Marcel Muller Patents

Resources

Home

Browse by:

Marcel Muller Patents

Inventor:

Muller; Marcel

Address:

Frenkendorf, CH

No. of patents:

Patents:

1 2

Patent Number	Title Of Patent	Date Issued
6150526	Piperidine derivative having renin inhibiting activity	November 21, 2000
Piperidine derivatives, their manufacture and use as medicaments, are disclosed. The invention is concerned with the piperidine derivatives of general formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, X, Z, m and n are as described herein.
6133442	Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antago	October 17, 2000
Compounds of formula I ##STR1## wherein R.sup.1 signifies phenyl, substituted phenyl or heterocyclyl;R.sup.2 signifies phenyl or substituted phenyl;R.sup.3 signifies hydrogen, lower-alkyl, cyano, carboxy, esterified carboxy, phenyl, substituted phenyl, heterocyclyl or a residue --CON
6051712	Piperidine derivatives having renin inhibiting activity	April 18, 2000
Novel piperidine derivatives, their manufacture and use as medicaments, are disclosed. The invention is concerned with the novel piperidine derivatives of general formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, Q, X, Z, m and n are as described herein.
6004965	Sulfonamides	December 21, 1999
Compounds of the formula: ##STR1## where A, B, R.sup.1 -R.sup.8 are as described herein are endothelin inhibitors that can be used in treating diseases associated with endothelin, such as high blood pressure. Chemical synthesis of these compounds and pharmaceutical compositions c
5973188	Acetic acid derivatives	October 26, 1999
Acetic acid derivatives of the formula ##STR1## wherein L, M, T and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive proteins to blood platelets and by blood platelet aggregatio
5962682	Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagon	October 5, 1999
Compounds of formula (I) ##STR1## wherein R.sup.1 signifies phenyl, substituted phenyl or heterocyclyl; R.sup.2 signifies phenyl or substituted phenyl; R.sup.3 signifies hydrogen, lower-alkyl, cyano, carboxy, esterified carboxy, phenyl, substituted phenyl, heterocyclyl or a resid
5856484	Sulfonylaminopyrimidine carboxylic acid derivatives having endothelin inhibiting activity	January 5, 1999
Compounds of formula I: ##STR1## are disclosed. The compounds inhibit the binding of endothelin to its receptors.
5837708	Sulphonamides	November 17, 1998
Compounds of the formula ##STR1## wherein the variables are hereinbelow defined. The compounds of formula I are inhibitors for endothelin receptors. They can be used for the treatment of disorders which are associated with endothelin activities, especially circulatory disorders s
5747522	Amino acid derivatives	May 5, 1998
N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R"' and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive proteins to blood platelets and by
5744460	Combination for treatment of proliferative diseases	April 28, 1998
The invention relates to combinations of PKC-targeted (especially PKC-.alpha.-targeted) deoxyribo- and ribo-oligonucleotides and derivatives thereof with other chemotherapeutic compounds, as well as to pharmaceutical preparations and/or therapies, in relation to disease states which
5726185	Acetic acid derivatives	March 10, 1998
Acetic acid derivatives of the formula ##STR1## wherein L, M, T and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive proteins to blood platelets and by blood platelet aggregatio
5670515	Amino acid derivatives	September 23, 1997
N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R'" and Q have the definitions given in the specification, are for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive proteins to blood platelets, by blood
5663297	Antithrombic peptides	September 2, 1997
Disclosed herein are peptide of the formulawherein R and R' are as defined herein. The claimed peptide derivatives inhibit platelet aggregation and as such are useful in the treatment of thrombosis.
5658928	Amino acid derivatives	August 19, 1997
N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R'" and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive proteins to blood platelets and by
5545658	Amino acid derivatives	August 13, 1996
N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R'" and Q have the significance given in the description, can be used for the treatment or prophylaxis of illnesses which are caused by the binding of adhesive proteins to blood platelets and by
5541186	Sulfonylaminopyrimidines	July 30, 1996
A compound of the formula ##STR1## wherein R.sup.1 to R, R.sup.a, R.sup.b X, Y, Z, m and n have the significance given in the description, can be used as medicaments, especially for the treatment and prophylaxix of conditions which are associated with endothelin activities.
5430024	Peptides bearing N-terminal amidino moieties and their use as inhibitors of platelet aggregation	July 4, 1995
Acetic acid derivatives of formulaand hydrates, solvates and physiologically acceptable salts thereof are useful to inhibit the binding of adhesive proteins to blood platelets and also to inhibit blood platelet aggregation and cell-cell adhesion.
5420129	Phenylsulfonylamide pyrimidine	May 30, 1995
The invention is concerned with novel sulphonamides and their use as medicaments. In particular, the invention is concerned with compounds of the formula ##STR1## wherein R.sup.1 is hydrogen, lower-alkyl, lower-alkoxy, lower-alkylthio, halogen or trifluoromethyl;R.sup.2 is hydrog
5399585	Carboxamides and sulfonamides compounds which have useful pharmaceutical utility	March 21, 1995
Novel carboxamides and sulfonamides are described having of the formulain which R.sup.1, A, W, X, Y, B, Z, R, a, b and c are as provided in the description. These compounds are useful in the treatment of thromboses, apoplexy, myocardial infarct, inflammations, arteriosclerosis as well as
5378712	Amino acid derivatives	January 3, 1995
N-Acyl-.alpha.-aminocarboxylic acid derivatives of the formula ##STR1## wherein L, R' to R"' and Q have the significance given in the description, can be used for the treatment or control of illnesses which are caused by the binding of adhesive proteins to blood platelets and by bloo
5278161	Amino acid derivatives useful as renin inhibitors	January 11, 1994
Compounds of the formula ##STR1## wherein A, B, X, Y, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as set forth in the specification, in the form of optically pure diastereomers, mixtures of diastereomers, diastereomeric racemates or mixtures of diasteromeric racemates as w
5273982	Acetic acid derivatives	December 28, 1993
Acetic acid derivatives of formulaand hydrates, solvates and physiologically acceptable salts thereof are useful to inhibit the binding of adhesive proteins to blood platelets and also to inhibit blood platelet aggregation and cell-cell adhesion.
5256812	Carboxamides and sulfonamides	October 26, 1993
Novel carboxamides and sulfonamides are described having of the formulain which R.sup.1, A, W, X, Y, B, Z, R, a, b and c are as provided in the description. These compounds are useful in the treatment of thromboses, apoplexy, myocardial infarct, inflammations, arteriosclerosis as well as
5166218	Phenoxypropanolamines and pharmaceutical compositions thereof	November 24, 1992
Tertiary and secondary amines of the formulas ##STR1## and ##STR2## wherein n is the integer 1 or 2,R is hydrogen, lower-alkanoyl or phenyl-lower-alkanoyl,X.sup.1 is phenoxymethyl optionally mono-fluorinated or mono-chlorinated in the ortho-position,X.sup.2 is lower-alkyl, phenox
5084466	Novel carboxamide pyridine compounds which have useful pharmaceutical utility	January 28, 1992
Novel carboxamides and sulfonamides are described having of the formulain which R.sup.1, A, W, X, Y, B, Z, R, a, b and c are as provided in the description. These compounds are useful in the treatment of thromboses, apoplexy, myocardial infarct, inflammations, arteriosclerosis as well as
5064863	Phenoxypropanolamines and pharmaceutical use	November 12, 1991
Tertiary and secondary amines of the formulas ##STR1## wherein n is the integer 1 or 2, p0 R is hydrogen, lower-alkanoyl or phenyl-lower-alkanoyl,X.sup.1 is phenoxymethyl optionally mono-fluorinated or mono-chlorinated in the ortho-position,X.sup.2 is lower-alkyl, phenoxymethyl optio
5039805	Novel benzoic and phenylacetic acid derivatives	August 13, 1991
The compound of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 have the significance given in the description, can be used as medicaments for the therapy and prophylaxis of disorders such as thromboses, stroke, cardiac infarct, inflammations and arteriosclerosis as wel
5017619	Phenethanolamine derivatives	May 21, 1991
The invention is directed to phenethanolamine derivatives and their pharmaceutically compatible salts, having the formula ##STR1## wherein n is the number 1 or 2; L.sup.1 and L.sup.2 are hydrogen, C.sub.1-3 -(alkyl)carbonyl or C.sub.1-3 (alkoxy) carbonyl; T is hydrogen or methyl;
4988714	Pyridine-ethanolamine derivatives	January 29, 1991
Pyridine-ethanolamines of the formula ##STR1## wherein n, X, Y, R.sup.1, R.sup.2 and R.sup.3 have the significances given in the description, their corresponding enantiomers, diastereomers, and racemates as well as the physiologically compatible salts thereof are described. The c
4892886	Phenoxypropanolamines	January 9, 1990
[p-[2-[[(S)-2-hydroxy-3-phenoxypropyl]amino]-ethyl]phenoxy]acetic acid and its physiologically compatible salts, which have catabolic activity and can be used for the treatment of obesity, of diabetes and of conditions which are associated with increased protein breakdown or as feed addi
4871755	Method for treating diabetes obesity and conditions characterized by increased protein breakdown	October 3, 1989
The oxazolidines of the formula ##STR1## wherein n signifies the number 1 or 2.T signifies lower carbalkoxy.X signifies phenoxymethyl optionally mono-fluorinated or mono-chlorinated in the ortho-position or phenyl optionally monosubstituted by fluorine, chlorine, trifluoromethyl or l
4800206	Pyridine-ethanolamine derivatives	January 24, 1989
Pyridine-ethanolamines of the formula ##STR1## wherein n, X, Y, R.sup.1, R.sup.2 and R.sup.3 have the significances given in the description, their corresponding enantiomers, diastereomers, and racemates as well as the pysiologically compatible salts thereof are describe. The com
4743604	Oxazolidines and compositions containing the same	May 10, 1988
The oxazolidines of the formula ##STR1## wherein n signifies the number 1 or 2,T signifies lower carbalkoxy,X signifies phenoxymethyl optionally mono-fluorinated or mono-chlorinated in the ortho-position or phenyl optionally monosubstituted by fluorine, chlorine, trifluoromethyl or l
4652679	Aziridine and phenethanolamine derivatives having antiobesity and anti-hyperglycaemic acitivity	March 24, 1987
Aziridine and phenethanolamine derivatives of formulae I and II-1 ##STR1## wherein R.sup.1 and R.sup.2 are hydrogen or lower-alkyl; Z.sup.1 is phenyl or a phenyl group substituted in a defined manner; Z.sup.2 and Z.sup.21 are phenyl or thienyl substituted in a defined manner; and, n
4585796	Novel phenethanolamines	April 29, 1986
The tertiary amines of the formula ##STR1## wherein n represents a whole number of 1 to 5;X.sup.1 represents phenyl or phenyl mono-, di- or tri-substituted by R.sup.1, R.sup.2 and R.sup.3 ;X.sup.2 represents hydrogen, lower-alkyl, phenyl or phenyl mono-, di- or tri-substituted by R.s
4578475	Novel D-homosteroids	March 25, 1986
The novel D-homosteroids of the formula ##STR1## wherein R.sup.1 represents a --CN, .dbd.NOH or .dbd.CH--NHOH group; R.sup.2 represents oxo or, where R.sup.1 represents a --CN group, R.sup.2 represents oxo or a --OAc group; or R.sup.1 and R.sup.2 together with carbon atoms 2 and
4492797	deA-steroids	January 8, 1985
The present disclosure is directed to 5-oxo- or methylene 17.beta.-hydroxy saturated or unsaturated deA-steroids wherein the 17.alpha.-position contains a propionic acid or propanol substituent and derivatives thereof wherein the hydroxy group at the 17-position forms a lactone ring with
4361578	D-Homosteroids	November 30, 1982
The invention is directed to 3-oxo-D-homosteroids and derivatives thereof which are useful as antiantigens.
4348327	Process for the preparation of 17.alpha.-hydroxy- and 17a.alpha.-hydroxy-D-homoetiocarboxylic ac	September 7, 1982
17.alpha.-hyroxy- and 17a.alpha.-hydroxy-D-homoetiocarboxylic acids of the formula ##STR1## wherein n is 1 or 2,A is ##STR2## and R.sub.1 is H or CH.sub.3are prepared by hydrating the corresponding 17-nitriles with a mixture of a lower carboxylic acid and its anhydride in the
4305603	Snow glider	December 15, 1981
A snow glider in the form of an elongated glide plate (1), the upper side of which has at least one stand-on area (2, 3) for the feet of the user and the front part of which is bent upwards in the manner of ski tips. The glide plate (1) is wider at the rear than at the front and in the m
4285880	D-Homopregnanes	August 25, 1981
D-Homopregnanes of the formula ##STR1## wherein X is hydrogen, Y is hydroxy or X and Y taken together denote an oxygen to carbon bond; R.sup.6 is hydrogen, R.sup.7 is hydrogen, lower alkanoylthio or aroylthio, or R.sup.6 and R.sup.7 taken together denote a carbon to carbon bond a
4272630	D-Homosteroids	June 9, 1981
The present invention is directed to 3-oxo, 6,9-hydro or halo, 11-oxo or (.alpha.--H,.beta.--OH), 17a-alkanoyloxy, 17a.beta.-carboxylate D-homosteroids which are useful as antiinflammatory agents.
4252729	Steroids and process for their manufacture	February 24, 1981
The present disclosure is concerned with 9.alpha.-chloro-17-(m-iodobenzyloxy) steroids and a process for their manufacture. The subject compounds are useful as intermediates in the synthesis of pharmacologically-active substances and have themselves been found to exhibit pharmacologi
4202841	D-Homopregnanes	May 13, 1980
D-Homopregnanes of the formula ##STR1## wherein the dotted line in the 1,2-position together with the corresponding solid line denotes a single or double carbon-carbon bond; R.sup.6 is hydrogen, fluoro, chloro or methyl; R.sup.9 is hydrogen, fluoro, chloro or bromo; R.sup.11 is h
4202823	D-Homopregnanes	May 13, 1980
D-Homopregnanes of the formula ##STR1## wherein X is hydrogen, Y is hydroxy or X and Y taken together denote an oxygen to carbon bond; R.sup.6 is hydrogen, R.sup.7 is hydrogen, lower alkanoylthio or aroylthio, or R.sup.6 and R.sup.7 taken together denote a carbon to carbon bond a
4197406	D-Homosteroids	April 8, 1980
The present disclosure is concerned with 17a-(m-iodobenzoyloxy) substituted D-homosteroids and a process for their manufacture. The compounds are useful as intermediates and also as hormonal agents, particularly progestational agents.
4155918	Novel D-homosteroids	May 22, 1979
The present disclosure relates to novel D-homosteroids. More particularly, the invention is concerned with hormonally active novel D-homosteroids, a process for the manufacture thereof and pharmaceutical preparations containing same.
4140700	D-Homopregnanes	February 20, 1979
D-Homopregnanes of the formula ##STR1## wherein X is hydrogen, Y is hydroxy or X and Y taken together denote an oxygen to carbon bond and the dotted line in the 1,2-position of the A-ring together with the corresponding solid line denotes a single or double carbon-to-carbon bond
4139716	19-Nor-D-homopregnanes	February 13, 1979
The present disclosure relates to D-homosteroids. More particularly, the disclosure is concerned with 19-nor-D-homopregnanes, a process for the manufacture thereof and pharmaceutical preparations containing same.
4137269	D-homosteroids	January 30, 1979
The present disclosure relates to steroids. More particularly, the disclosure is concerned with D-homosteroids, a process for the manufacture thereof and pharmaceutical preparations containing same. The subject D-homosteroids have high endocrinal activity and are particularly active